Retatrutide
The triple GLP-1/GIP/glucagon agonist — the most pronounced weight loss of its class.
iThe essentials in 10 seconds
- Most potent molecule in its class: acts on 3 receptors (GLP-1, GIP, glucagon)
- Greatest weight loss among current treatments (up to 24% in trials)
- Subcutaneous injection, once weekly, with gradual dose escalation
- Mandatory medical follow-up (digestive tolerance, pancreas, gallbladder)
IWhat is Retatrutide?
Retatrutide mimics three natural hormones involved in satiety and metabolism: GLP-1 and GIP (which suppress appetite and slow digestion) and glucagon (which increases energy expenditure). This triple action makes it more effective than single agonists. It is undergoing advanced clinical evaluation for obesity.
Recent treatment, data still maturing. Reserved for strict prescription and medical follow-up — never for self-medication.
The molecules presented on this site are innovative and fall under experimental use. Human data remain limited: a studied mechanism or a preclinical observation is not sufficient to demonstrate a benefit. The regulatory status in Morocco is not established for most of these peptides. Any use is decided within the framework of a medical consultation, with follow-up — never alone, never without an assessment.
IIThe benefits
Major reduction in appetite and caloric intake: the greatest weight loss in the class (up to ~24%).
Slows gastric emptying and acts on hunger centers: rapid and lasting feeling of fullness.
Strongly improves insulin sensitivity — major benefit in type 2 diabetes and prediabetes.
Glucagon action increases energy expenditure at rest (unlike GLP-1 agonists alone).
Reduces liver fat and lipid profile — useful in steatosis (fatty liver).
Improvement in blood pressure, triglycerides, and inflammation — targets of metabolic syndrome.
IIIRecommendations & how to use
Route: subcutaneous injection (abdomen/thigh), once weekly, preferably the same day · Escalation: start low and increase gradually to limit digestive effects · Storage: refrigerated (2–8 °C).
Treatment requires medical follow-up (tolerance, hydration, protein intake).
| Dosage | Price |
|---|---|
| 10 mg | Provided on request |
| 15 mg | Provided on request |
Prices are not published online: they are provided on request, during a consultation or by telephone.
IVThe two protocols
Goal: achieve lasting weight loss by increasing doses in steps, to minimize digestive effects.
Follow-up: weight, waist circumference, digestive tolerance, labs (blood glucose, lipids, liver).
Goal: preserve muscle mass during weight loss.
The peptide does not excuse lifestyle habits: it facilitates them.
VProtocol rules
- Sufficient protein intake to preserve muscle
- Drink regularly — hydration limits digestive effects
- Fiber-rich diet, smaller and more frequent meals
- Regular physical activity (walking + strength training)
- Record weight, tolerance, and satiety for follow-up
- Never self-medicate: medication requiring strict medical follow-up
- Do not exceed the dose or accelerate escalation
- Eating fatty/fried foods or overeating: triggers nausea and vomiting
- Excessive alcohol (pancreas, liver)
- Pregnancy, breastfeeding, history of pancreatitis or medullary thyroid cancer: contraindication
VIYour journey in 3 steps
Metabolic evaluation, contraindications, weight goals, injection training.
Stepwise increase every 4 weeks, according to tolerance and results.
Weight, body composition, labs — decision on next phase.
VIISide effects & level of evidence
- Nausea, vomiting
- Diarrhoea or constipation
- Marked appetite loss, fatigue
- Increased heart rate
- Rare: pancreatitis, gallstones; muscle mass loss
- Pregnancy and no effective contraception
- History of pancreatitis
- Severe renal impairment: caution
- Hypersensitivity
Non-exhaustive list based on the available literature and known class effects; it replaces neither a product label nor an individual medical assessment.
VIIIPublications & references
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialJastreboff et al. · N Engl J Med · 2023 · PMID 37366315
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsGiblin et al. · Diabetes Obes Metab · 2026 · PMID 41090431
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialSanyal et al. · Nat Med · 2024 · PMID 38858523
Documentary references: the existence of a publication establishes neither efficacy nor safety for personal use. The regulatory status in Morocco must be verified.